Alzheimer Disease Agents Drug Class Prior Authorization Protocol
|
|
- Erika Dalton
- 5 years ago
- Views:
Transcription
1 Line of Business: Medi-Cal Effective Date: August 16, 2017 Revision Date: August 16, 2017 Alzheimer Disease Agents Drug Class Prior Authorization Protocol This policy has been developed through review of medical literature, consideration of medical necessity, generally accepted medical practice standards, and approved by the IEHP Pharmacy and Therapeutics Subcommittee. Drugs: Aricept (donepezil, donepezil ODT), Exelon (rivastigmine), Exelon (rivastigmine transdermal patch), Namenda (memantine), Namenda XR (memantine ER), Namzaric (memantine, donepezil ER), Razadyne (galantamine), Razadyne ER (galantamine ER) FDA Approved Indications: Aricept (donepezil), Donepezil ODT, Galantamine oral solution, Namenda (memantine), Namenda XR (memantine ER), Namzaric (memantine, donepezil ER), Razadyne (galantamine), Razadyne ER (galantamine ER) Exelon (rivastigmine), Exelon (rivastigmine transdermal patch) Alzheimer dementia Parkinson-related dementia
2 Policy/ * Generic-mandatory protocol applies. Please refer to the Brand Name Drug Request Policy. A. Drug: Exelon (rivastigmine transdermal patch)* b. Parkinson s disease dementia : i. Failure or clinically significant adverse effects to two formulary cholinesterase inhibitors (e.g. donepezil, donepezil ODT, rivastigmine, galantamine) ii. Documented difficulty swallowing (i.e. dysphagia) AND failure or clinically significant adverse effects to formulary donepezil ODT b. Parkinson s disease dementia: iii. Failure or clinically significant adverse effects to rivastigmine capsule iv. Documented difficulty swallowing (i.e. dysphagia) B. Drug: Galantamine Oral Solution* a. Failure or clinically significant adverse effects to two formulary cholinesterase inhibitors (e.g. donepezil, donepezil ODT, rivastigmine, galantamine) b. Documented difficulty swallowing (i.e. dysphagia) AND failure or clinically significant adverse effects to formulary donepezil ODT
3 C. Drug: Namenda XR (memantine ER) a. Failure or clinically significant adverse effects to formulary memantine 12 months D. Drug: Namzaric (memantine, donepezil ER) a. Medical justification why formulary donepezil and Namenda ER cannot be used concurrently E. Drug: Razadyne ER (galantamine ER)* a. Failure or clinically significant adverse effects to two formulary cholinesterase inhibitors (e.g. donepezil, donepezil ODT, rivastigmine, galantamine)
4 Clinical Justification: Current Pharmacologic Treatment of Dementia: A Clinical Practice Guideline from the American College of Physicians and the American Academy of Family Physicians 2008 Recommendation 1: Clinicians should base the decision to initiate a trial of therapy with a cholinesterase inhibitor or memantine on individualized assessment (Grade: weak recommendation, moderate-quality evidence) o The decision to initiate therapy should be based on evaluation of benefits and risks associated with an individual patient o Although the evidence shows statistically significant benefits of treatment with some cholinesterase inhibitors and memantine for all kinds of dementia, these benefits, on average, are not clinically significant for cognition and are modest for global assessments. o Limited evidence suggests, but does not demonstrate conclusively, that a subgroup of patients achieves clinically important improvement. o Evidence is insufficient to determine the optimal duration of therapy. o A beneficial effect, if any, would generally be observed within 3 months on the basis of duration of trails. o No evidence demonstrates when it is appropriate to stop the treatment if the patient becomes unresponsive or shows decline in various domains of dementia. o If slowing decline is no longer a goal, treatment with memantine or a cholinesterase inhibitor is no longer appropriate. Recommendation 2: Clinicians should base the choice of pharmacologic agents on tolerability, adverse effect profile, ease of use and cost of medication. The evidence is insufficient to compare the effectiveness of different pharmacologic agents for the treatment of dementia. (Grade: weak recommendation, low quality-evidence) o Because few trials compare one drug with another, evidence about effectiveness is insufficient to support the choice of specific drugs for the treatment of dementia. Recommendation 3: There is an urgent need for further research on the clinical effectiveness of pharmacologic management of dementia Effectiveness of Cholinesterase Inhibitors and Memantine for Treating Dementia: Evidence Review for a Clinical Practice Guideline 2008
5 96 publications representing 59 unique studies were eligible for this review Both cholinesterase inhibitors and memantine had consistent effects in the domains of cognition and global assessment, but summary estimates showed small effect sizes Clinically important differences were not consistently evaluated or demonstrated in these two domains for all drugs Outcomes in the domains of behavior and quality of life were evaluated less frequently and showed less consistent effects Direct comparison among these drugs are limited and do not suggest important differences References: 1. Qaseem A, Snow V, Cross JT, et al. Current pharmacologic treatment of dementia: a clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians. Ann Intern Med. 2008; 148(5): Raina P, Santaguida P, Ismaila A, et al. Ann Intern Med. 2008; 148(5): Namzaric [package insert]. Cincinnati, Ohio: Forest Pharmaceuticals Inc.; Feb Aricept [package insert]. New York, NY: Pfizer Inc.; July Exelon [package insert]. East Hanover, NH: Novartis Pharmaceuticals Inc.; Oct Exelon Patch [package insert]. East Hanover, NH: Novartis Pharmaceuticals Inc.; Feb Razadyne [package insert]. Titusville, NJ: Janssen Pharmaceuticals Inc.; July Namenda [package insert]. Cincinnati, Ohio: Forest Pharmaceuticals Inc.; Oct, Change Control Date Change 08/16/2017 Removed Galantamine 4 mg/ml oral solution from Medi-Cal Formulary Added Memantine 5 mg tablet and 10 mg tablet to Medi-Cal Formulary
See Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Memantine ER (Namenda XR), galantamine (Razadyne, Razadyne ER) Reference Number: CP.CPA.102 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See
More informationCentral Nervous System Stimulants Drug Class Prior Authorization Protocol
Line of Business: Medi-Cal Effective Date: August 16, 2017 Revision Date: August 16, 2017 Central Nervous System Stimulants Drug Class Prior Authorization Protocol This policy has been developed through
More informationLiterature Scan: Alzheimer s Drugs
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationClinical Policy: Rivastigmine (Exelon) Reference Number: CP.PMN.101 Effective Date: Last Review Date: 02.18
Clinical Policy: (Exelon) Reference Number: CP.PMN.101 Effective Date: 03.01.17 Last Review Date: 02.18 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important
More information1. Developed April Revised May 2017; November 2015; March 2014; March 2012.
Texas Vendor Drug Program Drug Use Criteria: Memantine (Namenda ) Publication History 1. Developed April 2010. 2. Revised May 2017; November 2015; March 2014; March 2012. Notes: Information on indications
More informationAppendix K: Evidence review flow charts
K.1 Dementia diagnosis K.1.1 Dementia diagnosis What are the most effective methods of primary assessment to decide whether a person with suspected dementia should be referred to a dementia service? What
More informationAlzheimer dementia: Starting, stopping drug therapy
REVIEW LUKE D. KIM, MD, FACP, CMD Assistant Professor of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH; Center for Geriatric Medicine, Medicine
More informationHuiwen Deng, Sarah Lothspeich, Darin Meinen, Abigail Sakellaris Mentored by Dr. Urmie
Huiwen Deng, Sarah Lothspeich, Darin Meinen, Abigail Sakellaris Mentored by Dr. Urmie Formularies are important for patient access Cost affects adherence Formularies differ between plans Especially regarding
More informationMonth/Year of Review: September 2013 Date of Last Review: February 2012
Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119 Copyright 2012 Oregon State University. All Rights
More informationMethylphenidate Dexmethylphenidate
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.60.25 Yeah Subject: Methylphenidates Page: 1 of 6 Last Review Date: September 15, 2017 Methylphenidate
More informationDementia is not normal aging!
The Future of Alzheimer s Disease Treatment Adam L. Boxer, MD, PhD Director, Alzheimer s Disease Clinical Trials Program Memory and Aging Center Assistant Professor of Neurology University of California,
More informationPharmacy Medical Necessity Guidelines: ADHD CNS Stimulant Medications
Pharmacy Medical Necessity Guidelines: ADHD CNS Stimulant Medications Effective: November 13, 2018 Prior Authorization Required Type of Review Care Management Not Covered Type of Review Clinical Review
More informationTSHP 2014 Annual Seminar 1
MANAGING LATE STAGE ALZHEIMER S DISEASE- A PALLIATIVE APPROACH Nakia A. Beard, PharmD, CGP Assistant Professor of Pharmacy Practice, Division of Geriatrics Texas Tech University Health Sciences Center
More informationMedications for Alzheimer s disease: are they right for you?
Medications for Alzheimer s disease: are they right for you? There are no medications today that can cure Alzheimer s disease. But there are currently four medications approved by Health Canada which can
More informationPharmacy Policy Bulletin
Pharmacy Policy Bulletin Title: Policy #: Age Edits Rx.01.2 Application of pharmacy policy is determined by benefits and contracts. Benefits may vary based on product line, group, or contract. Some medications
More informationMethylphenidate Dexmethylphenidate
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Methylphenidates Page: 1 of 7 Last Review Date: November 30, 2018 Methylphenidate Dexmethylphenidate
More informationAlthough cholinesterase inhibitors (ChEIs) and memantine
High-dose donepezil or memantine: Next step for Alzheimer s disease? Larger dosages may benefit patients who have maxed out existing therapies Indrapal Singh, MD Assistant Professor Department of Geriatric
More informationOVERVIEW FOOD AND DRUG ADMINISTRATION-APPROVED INDICATIONS
Pharmacy Medical Necessity Guidelines: Effective: September 18, 2017 Prior Authorization Required Type of Review Care Management Not Type of Review Clinical Review Pharmacy (RX) or Medical (MED) Benefit
More informationPsychotropic Strategies Handout Package
Psychotropic Strategies Handout Package Psychotropic Strategies Learning Objectives Utilize all clinical information available Assess the patient s overall condition this is essential Basic Principles
More informationMethylphenidate also has an off-label indication for depression, although published trials are limited in size and duration (14).
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.60.25 Yeah Subject: Methylphenidates Page: 1 of 5 Last Review Date: December 2, 2016 Methylphenidate
More informationDiagnosis and Treatment of Alzhiemer s Disease
Diagnosis and Treatment of Alzhiemer s Disease Roy Yaari, MD, MAS Director, Memory Disorders Clinic, Banner Alzheimer s Institute 602-839-6900 Outline Introduction Alzheimer s disease (AD)Guidelines -revised
More informationAnti-Obesity Agents Drug Class Prior Authorization Protocol
Anti-Obesity Agents Drug Class Prior Authorization Protocol Line of Business: Medicaid P & T Approval Date: February 21, 2018 Effective Date: March 1, 2018 This policy has been developed through review
More informationPage: 1 of 5. Methylphenidate also has an off-label indication for depression, although published trials are limited in size and duration (12).
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.06.25 Page: 1 of 5 Last Review Date: June 19, 2015 Description Concerta / Daytrana / Metadate CD / Metadate
More informationEARLY DEMENTIA. University of Hawaii Geriatric Medicine Department
EARLY DEMENTIA University of Hawaii Geriatric Medicine Department INTRODUCTION Dementia is very prevalent Screening and early diagnosis is important Evaluation Dementia Management DEMENTIA IS VERY PREVALENT
More informationMental Health Subcommittee of PTAC meeting held 21 June (minutes for web publishing)
Mental Health Subcommittee of PTAC meeting held 21 June 2010 (minutes for web publishing) Mental Health Subcommittee minutes are published in accordance with the Terms of Reference for the Pharmacology
More informationDisclosure. Speaker Bureaus. Grant Support. Pfizer Forest Norvartis. Pan American Health Organization/WHO NIA HRSA
Disclosure Speaker Bureaus Pfizer Forest Norvartis Grant Support Pan American Health Organization/WHO NIA HRSA How Common is Psychosis in Alzheimer s Disease? Review of 55 studies 41% of those with Alzheimer
More informationAlzheimer s disease Treatment options
Alzheimer s disease Treatment options Treatment options Recent research has greatly improved our knowledge of Alzheimer s disease. Treatments for the disease are now available that may help to alleviate
More informationAricept, Exelon and Reminyl the new drugs for Alzheimer s disease
PBO 930022142 NPO 049-191 Aricept, Exelon and Reminyl the new drugs for Alzheimer s disease Aricept, Exelon and Reminyl are not cures for Alzheimer s disease. However, they can temporarily slow down the
More informationA 24-Week, Open-Label Extension Study to Investigate the Long-Term Safety,
1 A 24-Week, Open-Label Extension Study to Investigate the Long-Term Safety, Tolerability, and Efficacy of 13.3 mg/24 h Rivastigmine Patch in Patients with Severe Alzheimer s Disease Martin R. Farlow,
More informationMemory Loss, Dementia and Alzheimer's Disease: The Basics
Memory Loss, Dementia and Alzheimer's Disease: The Basics What is memory loss? What is age-related memory loss? Typical changes Typical age-related changes involve: Making a bad decision once in a while
More informationPharmacy Drug Class Review
April 16, 2010 Pharmacy Drug Class Review Disclaimer: Specific agents may have variations Dementia Review Focus on available treatments for Alzheimer s disease Authored By: Sarah Davis, Pharm.D Candidate
More informationUnderstanding Dementia
Understanding Dementia Dr. Dallas Seitz MD FRCPC Assistant Professor, Department of Psychiatry, Queen s University, Kingston, Ontario, Canada What s Next Information about Dementia, Elder Care and Supports
More informationDr. Michael Lobatz Dr. Michael Jackson Dr. James Brewer Dr. Paul Aisen. Dr. Michael Plopper. Dr. Guerry Peavy
1 Anne State 2 3 Dr. Michael Lobatz Dr. Michael Jackson Dr. James Brewer Dr. Paul Aisen Dr. Michael Plopper Dr. Guerry Peavy 4 Michael Lobatz, MD Medical Director, Neurosciences Medical Director, Rehabilitation
More informationDementia Medications Acetylcholinesterase Inhibitors (AChEIs) and Glutamate (NMDA) Receptor Antagonist
Dementia Medications Acetylcholinesterase Inhibitors (AChEIs) and Glutamate (NMDA) Receptor Antagonist Medication Dosage Indication for Use Aricept (donepezil) Exelon (rivastigmine) 5mg 23mg* ODT 5mg Solution
More informationThe Alzheimers Solution A Revolutionary Guide To How You Can Prevent And Reverse Memory Loss
The Alzheimers Solution A Revolutionary Guide To How You Can Prevent And Reverse Memory Loss We have made it easy for you to find a PDF Ebooks without any digging. And by having access to our ebooks online
More informationDementia. Memory Evaluation Center Neurology
Dementia Memory Evaluation Center Neurology Topics Overview of dementia Stages Medications Advanced planning What is Dementia? Dementia = significant global decline in cognitive function not due to medicine
More informationAlzheimer's disease (AD), also known as Senile Dementia of the Alzheimer Type (SDAT) or simply Alzheimer s is the most common form of dementia.
CHAPTER 3 Alzheimer's disease (AD), also known as Senile Dementia of the Alzheimer Type (SDAT) or simply Alzheimer s is the most common form of dementia. This incurable, degenerative, terminal disease
More informationQUANTITY LIMIT CRITERIA
DRUG CLASS (ADHD) AGENTS BRAND NAME (generic) QUANTITY LIMIT CRITERIA ATTENTION DEFICIT HYPERACTIVITY DISORDER ADDERALL (amphetamine mixture) ADDERALL XR (amphetamine extended-release mixture) ADZENYS
More informationALZHEIMER'S DRUGS. Details. Step 2: Exelon Patch 13.3 mg/24 hour transdermal Exelon Patch 4.6 mg/24 hr transdermal
ALZHEIMER'S DRUGS Products Affected Step 1: donepezil 10 mg disintegrating tablet donepezil 10 mg tablet donepezil 23 mg tablet donepezil 5 mg disintegrating tablet donepezil 5 mg tablet galantamine 12
More informationPharmacy Medical Necessity Guidelines: ADHD CNS Stimulant Medications
Pharmacy Medical Necessity Guidelines: ADHD CNS Stimulant Medications Effective: January 1, 2018 Prior Authorization Required Type of Review Care Management Not Covered Type of Review Clinical Review Pharmacy
More informationDrug Class Monograph
Drug Class Monograph Class: Oral Anticoagulants Drug: Coumadin (warfarin), Eliquis (apixaban), Pradaxa (dabigatran), Savaysa (edoxaban), arelto (rivaroxaban) Formulary Medications: Eliquis (apixaban),
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Health Technology Appraisal
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Health Technology Appraisal Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (Review of TA 111) Appraisal
More informationDementia Pharmacotherapy
Dementia Pharmacotherapy 1 early therapeutic interventions can maximize pharmacologic efficacy with these agents 2 Selecting a Medication Not enough evidence to recommend one agent over another based on
More informationSHARED CARE PROTOCOL CHOLINESTERASE INHIBITORS IN ALZHEIMER S DEMENTIA
SHARED CARE PROTOCOL CHOLINESTERASE INHIBITORS IN ALZHEIMER S DEMENTIA Introduction Alzheimer s disease is the most common cause of dementia. It is characterised by an insidious onset of global mental
More informationClinical Policy: CNS Stimulants Reference Number: CP.PMN.92 Effective Date: Last Review Date: Line of Business: Commercial, Medicaid
Clinical Policy: Reference Number: CP.PMN.92 Effective Date: 03.01.18 Last Review Date: 02.18 Line of Business: Commercial, Medicaid Revision Log See Important Reminder at the end of this policy for important
More informationUnitedHealthcare Pharmacy Clinical Pharmacy Programs. Program Number 2017 P Prior Authorization/Notification CNS Stimulants
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2017 P 1020-6 Program Prior Authorization/Notification CNS Stimulants Medication Adderall* (amphetamine-dextroamphetamine mixed salts),
More informationGeneric Name (Brand Name) Available Strengths Formulary Limits. Primidone (Mysoline) 50mg, 250mg -- $
MEDICATION COVERAGE POLICY PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE POLICY: Epilepsy P&T DATE: 2/15/2017 THERAPEUTIC CLASS: Neurologic Disorders REVIEW HISTORY: 2/16 LOB AFFECTED: Medi-Cal (MONTH/YEAR)
More informationPharmacy Medical Necessity Guidelines: CNS Stimulant Medications
Pharmacy Medical Necessity Guidelines: CNS Stimulant Medications Effective: June 1, 2017 Prior Authorization Required Type of Review Care Management Not Covered Type of Review Clinical Review Pharmacy
More informationClinical Policy: CNS Stimulants Reference Number: CP.PMN.XX Effective Date: Last Review Date: Line of Business: Commercial, Medicaid
Clinical Policy: Reference Number: CP.PMN.XX Effective Date: 03.01.18 Last Review Date: 02.18 Line of Business: Commercial, Medicaid Revision Log See Important Reminder at the end of this policy for important
More informationScreening Summary (SS2)
15Screening SummarySS217 Aug 06 Depression in Alzheimer s Disease Study - 2 DIADS-2 Screening Summary (SS2) Keyed: ( ) Purpose: Document findings about eligibility for DIADS-2 and about medical and social
More informationDementia Basics. Welcome! What to expect and how to handle a dementia diagnosis. In partnership with Scripps Health.
Dementia Basics What to expect and how to handle a dementia diagnosis March 18, 2017 In partnership with Scripps Health Welcome! 1 Welcome Kristin Gaspar San Diego County Supervisor District 3 2 Our Mission:
More informationMedication for Dementia (Acetylcholinesterase Inhibitors)
Medication for Dementia (Acetylcholinesterase Inhibitors) ^ ãéãäéê çñ `~ãäêáçöé råáîéêëáíó eé~äíü m~êíåéêë What are they? A group of medications used to help treat the symptoms of dementia in the mild
More information(Incidence, Treatments, Key Companies, Pipeline and Trends)
World Alzheimer's Disease Market (Incidence, Treatments, Key Companies, Pipeline and Trends) CHAPTER ONE: EXECUTIVE SUMMARY Background Scope and Methodology Size and Growth of the Market Key Issues and
More information4/11/2017. The impact of Alzheimer s disease. Typical changes. The impact of Alzheimer s disease. Problematic changes. Problematic changes
The impact of Alzheimer s disease Ron Petersen, MD, PhD, is Director of the Mayo Alzheimer's Disease Research Center. 2 The impact of Alzheimer s disease Typical changes Typical age-related changes involve:
More informationManagement of Alzheimer s Disease Dementia
Management of Alzheimer s Disease Dementia Andrea Butler, PharmD Pharmacy Practice Resident FAMU College of Pharmacy and Pharmaceutical Sciences Apalachee Center, Inc. 2018 1 Disclosure I do not have a
More informationDrug Update. Treatments for Cognitive Impairment in the Older Adult. William Solan, M.D. Karen Sanders, Ph.D. Northwest Hospital Seattle
Drug Update Treatments for Cognitive Impairment in the Older Adult William Solan, M.D. Karen Sanders, Ph.D. Northwest Hospital Seattle Current Drug Treatments for Alzheimer s Disease Cholinesterase Inhibitors:
More informationOsteoporosis Agents Drug Class Prior Authorization Protocol
Osteoporosis Agents Drug Class Prior Authorization Protocol Line of Business: Medicaid P&T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed through review of
More informationDementia of the Alzheimer Type: the Drug Treatment Debate
Dementia of the Alzheimer Type: the Drug Treatment Debate I have no financial conflict of interest. Many years ago I was given a trip to San Fran and taught to use a slide set from the drug company. I
More informationOverview of Alzheimer s Disease
Overview of Alzheimer s Disease Today s Objectives Provide an overview of Alzheimer s disease and related dementias Where can individuals, families and professionals get help Services available What is
More informationSignificance A Busy Clinician's Guide to Seniors with Memory Loss
Significance A Busy Clinician's Guide to Seniors with Memory Loss Victoria Braund MD FACP CMD Division of Geriatrics. NorthShore University HealthSystem Alzheimer's disease is the sixth leading cause of
More informationUnitedHealthcare Pharmacy Clinical Pharmacy Programs
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2018 P 3001-11 Program Step Therapy - Anticonvulsants Medication/Therapeutic Class Anticonvulsants Depakote, Depakote ER, Felbatol, Keppra,
More informationCorium Investor Update 16 th Annual Needham Healthcare Conference
Nasdaq: CORI Corium Investor Update 16 th Annual Needham Healthcare Conference April 4-5, 2017 Forward-looking Statements This presentation and the accompanying oral presentation contain forward-looking
More informationDonepezil, galantamine, rivastigmine (review) and memantine for the treatment of Alzheimer s disease (amended)
Issue date: November 2006 (amended September 2007) Review date: September 2009 Donepezil, galantamine, rivastigmine (review) and memantine for the treatment of Alzheimer s disease (amended) Includes a
More informationDrug treatments for Alzheimer s disease
Drug treatments for Alzheimer s disease Factsheet 407LP April 2018 There are no drug treatments that can cure Alzheimer s disease or any other common type of dementia. However, there are medicines for
More informationPharmacy Medical Necessity Guidelines: Migraine Medications
Pharmacy Medical Necessity Guidelines: Effective: September 18, 2017 Prior Authorization Required Type of Review Care Management Not Covered Type of Review Clinical Review Pharmacy (RX) or Medical (MED)
More informationThe Basics of Alzheimer s Disease
2017 Memory Loss Conference The Basics of Alzheimer s Disease Tom Ala, MD Center for Alzheimer s Disease and Related Disorders Southern Illinois University School of Medicine Springfield, Illinois SIU
More informationPharmacological Treatment of Dementia
Pharmacological Treatment of Dementia Measure Description Percentage of patients with dementia or their caregivers with whom available guideline-appropriate pharmacological treatment options and nonpharmacological
More informationUNDERSTANDING ALZHEIMER S AND DEMENTIA
UNDERSTANDING ALZHEIMER S AND DEMENTIA Geri T., living with Alzheimer's, and her husband and care partner, Jim T. THE IMPACT OF ALZHEIMER S AND DEMENTIA Currently, an estimated 50 million people worldwide
More informationDrug Class Monograph. Policy/Criteria:
Drug Class Monograph Class: Pulmonary Arterial Hypertension Agents Drugs: Adcirca (tadalafil), Adempas (riociguat), Flolan (epoprostenol), Letairis (ambrisentan), Opsumit (macitentan), Orenitram (treprostinil),
More informationAlameda Alliance for Health Pharmacy & Therapeutics (P&T) Committee Decisions
Alameda Alliance for Health FORMULARY UPDATE Effective: October 27, 2017. Drugs notated with an * have an undetermined implementation date Alameda Alliance for Health Pharmacy & Therapeutics (P&T) Committee
More information2018 Step Therapy Criteria (List of Step Therapy Criteria)
Step Therapy Criteria Last Updated: March 20, 2018 Effective Date: April 1, 2018 2018 Step Therapy Criteria (List of Step Therapy Criteria) PLEASE READ CAREFULLY: IEHP DUALCHOICE CAL MEDICONNECT PLAN (MEDICARE-MEDICAID
More informationManaging Patients with Dementia using a Collaborative and Strength-based Approach
Managing Patients with Dementia using a Collaborative and Strength-based Approach Therapy Network Seminars, Inc. Nicole Dawson, PT, PhD, GCS Learning Objectives The Participant will be able to: Identify
More informationEssential Shared Care Agreement Drugs for Dementia
E098 Essential Shared Care Agreement Drugs for Dementia Please complete the following details: Patient s name, address, date of birth Consultant s contact details (p.3) And send One copy to: 1. the patient
More informationPL CE LIVE May 2012 Forum
CE Information CE Information Pharmacist's Letter / Therapeutic Research Center is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.
More informationAETNA BETTER HEALTH Prior Authorization guideline for Narcotic Analgesic Utilization
AETNA BETTER HEALTH Prior Authorization guideline for Narcotic Analgesic Utilization Policy applies to all formulary and non-formulary schedules II V opioid narcotics, including tramadol and codeine, as
More information2018 Step Therapy Criteria (List of Step Therapy Criteria)
Criteria Last Updated: October 05, 2017 Effective Date: January 1, 2018 2018 Step Therapy Criteria (List of Step Therapy Criteria) PLEASE READ CAREFULLY: IEHP DUALCHOICE CAL MEDICONNECT PLAN (MEDICARE-
More informationAnnouncing FDA Approval of GOCOVRI TM
Announcing FDA Approval of GOCOVRI TM August 24, 2017 2017 Adamas Pharmaceuticals, Inc. All Rights Reserved. 1 Forward-looking Statements Statements contained in this presentation regarding expected future
More informationPharmacological Treatment of Behavioural and Psychological Symptoms of Dementia (BPSD) Gurdeep K Major St. Charles Hospital
Pharmacological Treatment of Behavioural and Psychological Symptoms of Dementia (BPSD) Gurdeep K Major St. Charles Hospital with thanks to Jonathan Cavan for his input Aims Define BPSD and common symptoms
More informationOutcome measures in neuroscience clinical trials
Neuroscience TM Outcome measures in neuroscience clinical trials Jang-Ho Cha, Head, Translational Medicine Neuroscience Novartis Institute for BioMedical Research February 2017 Outline What is our problem?
More informationUnitedHealthcare Pharmacy Clinical Pharmacy Programs
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2017 P 2004-10 Program Prior Authorization/Medical Necessity - Multisource Brand/Modified Release Anticonvulsants Medication/Therapeutic
More informationIf a bad thing is happening to a patient, a drug did it until proven otherwise
Dr Vicki s First Rule of Geriatrics Deprescribing in the Elderly Victoria Braund MD, FACP, CMD Director, Division of Geriatrics NorthShore University HealthSystem Medical Director, Brandel Health & Rehab
More informationPrescribing Framework for Rivastigmine in the Treatment and Management of Dementia
Hull & East Riding Prescribing Committee Prescribing Framework for Rivastigmine in the Treatment and Management of Dementia Patients Name:.. NHS Number: Patients Address:... (Use addressograph sticker)
More informationTechnology appraisal guidance Published: 23 March 2011 nice.org.uk/guidance/ta217
Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease Technology appraisal guidance Published: 23 March 2011 nice.org.uk/guidance/ta217 NICE 2017. All rights reserved.
More informationEssential Shared Care Agreement Drugs for Dementia
Ref No. E052 Please complete the following details: Patient s name, address, date of birth Consultant s contact details (p.3) And send One copy to: 1. the patient s GP 2. put one copy in care plan 3. give
More informationASK IF NAMZARIC MAY BE RIGHT FOR THEM.
IF YOUR LOVED ONE WITH MODERATE ALZHEIMER S IS TAKING DONEPEZIL 10 MG, ASK IF NAMZARIC MAY BE RIGHT FOR THEM. Once-daily NAMZARIC is a prescription medicine approved to treat moderate to severe Alzheimer
More informationWhat are we getting right and what are we getting wrong?
What are we getting right and what are we getting wrong? GERARD BYRNE BSc (Med), MBBS (Hons), PhD, FRANZCP School of Medicine University of Queensland Some Important Goals Understanding the causes of dementia
More informationA BRIEF LOOK AT DEMENTIA
Dementia A BRIEF LOOK AT DEMENTIA David Kaufman, MD Neurology Consultants of Bellin Health November 2, 2017 Defined as a progressive decline in cognitive function that impairs daily activities. Always
More informationPharmacy Policy Bulletin
Pharmacy Policy Bulletin Title: Policy #: Applicable Age Edits Rx.01.2 Application of pharmacy policy is determined by benefits and contracts. Benefits may vary based on product line, group, or contract.
More informationCantor Global Healthcare Conference
Nasdaq: CORI Cantor Global Healthcare Conference September 2017 Forward-looking Statements This presentation and the accompanying oral presentation contain forward-looking statements that are based on
More informationDRUG THERAPY CHOICES FOR THE DEMENTED PATIENT Past, Present and Future
DRUG THERAPY CHOICES FOR THE DEMENTED PATIENT Past, Present and Future Daniel S. Sitar Professor Emeritus University of Manitoba Email: Daniel.Sitar@umanitoba.ca March 6, 2018 INTRODUCTION EPIDEMIOLOGY
More informationOral Anticoagulation Drug Class Prior Authorization Protocol
Oral Anticoagulation Drug Class Prior Authorization Protocol Line of Business: Medicaid P & T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed through review
More informationRational Medication Use in Dementia
Rational Medication Use in Dementia Stephen Thielke sthielke@u.washington.edu (206) 764 2815 I have no conflicts of interest to report. I am an employee of the federal government. The opinions in this
More informationAlzheimer s Disease Update: From Treatment to Prevention
Alzheimer s Disease Update: From Treatment to Prevention Jeffrey M. Burns, MD Edward H. Hashinger Professor of Medicine Co-Director, KU Alzheimer s Disease Center Director, Clinical and Translational Science
More informationUnitedHealthcare Pharmacy Clinical Pharmacy Programs
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2018 P 2004-12 Program Prior Authorization/Medical Necessity - Multisource Brand/Modified Release Anticonvulsants Medication/Therapeutic
More informationREFERENCE CODE GDHC98PIDR PUBLICATION DATE FEBRUARY 2015 ALZHEIMER S DISEASE GLOBAL DRUG FORECAST AND MARKET ANALYSIS TO 2023
REFERENCE CODE GDHC98PIDR PUBLICATION DATE FEBRUARY 2015 ALZHEIMER S DISEASE GLOBAL DRUG FORECAST AND MARKET ANALYSIS TO 2023 Executive Summary Table below presents the key metrics for Alzheimer s disease
More informationLeading an Alzheimer s/dementia Care Unit
Leading an Alzheimer s/dementia Care Unit Review of Dementia and Care Practices In this section, we will cover: Definition of dementia and Alzheimer s disease Alzheimer s disease progression Importance
More informationDiscontinuing Dementia Medications Case April Patient Case
Discontinuing Dementia Medications Case April 2017 Patient Case MJ is an 86 year-old female with a primary diagnosis of Alzheimer s disease and history of anemia, cystitis, depression, Type II DM, HTN,
More informationMedication Treatments for Dementia. Stephen Thielke
Medication Treatments for Dementia Stephen Thielke Treatment is a MORAL decision. Facts can help you determine HOW to accomplish something. Facts cannot tell you WHAT YOU WANT to accomplish. Dementia Meds
More informationAlzheimer s disease. The facts in brief
Alzheimer s disease Dementia is an umbrella term used to describe various conditions which damage brain cells and lead to a loss of brain function over time. Dementia causes a progressive decline in a
More informationBasal Insulin Drug Class Prior Authorization Protocol
Basal Insulin Drug Class Prior Authorization Protocol Line of Business: Medicaid P&T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed through review of medical
More information